So for NAION, knowing that by taking this medication you are putting yourself at a slight increase of that happening, though again, the chances are extremely rare. While some studies have shown a possible concern for the development of NAION, Dr
Regulatory bodies approved GLP-1 receptor agonists are TRULICITY (dulaglutide), BYETTA/BYDUREON (exenatide), VICTOZA (liraglutide), OZEMPIC/WEGOVY/RYBELSUS, (Semaglutide), MOUNJARO/ZEPBOUND (tirzepatide) and others
The STEP-1 follow-up data for Semaglutide showed that participants who discontinued the medication regained approximately two-thirds of their lost weight within one year without significant lifestyle intervention
NINA MOINI: Why might older adults in particular benefit from greater access to these GLP-1s
A section reserved for HealthVerity Marketplace data illustrates the richness of real-world evidence available to inform strategic decisions